Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine

References

• Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.
   PubMed Web of Science ®Google Scholar
• Adeloye D, Chua S, Lee C, Basquill C, Papana A, Theodoratou E, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2):020415.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Burden of COPD. Geneva: World Health Organization. 2015 [accessed 2016 August 8]. http://wwwwhoint/respiratory/copd/burden/en/.
   Google Scholar
• Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L. Definition, epidemiology and natural history of COPD. Eur Respir J. 2007;30(5):993–1013.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Puxeddu E, Bettoncelli G, Novelli L, Segreti A, Cricelli C, et al. The prevalence of asthma and COPD in Italy: a practice-based study. Respir Med. 2011;105(3):386–91.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonart diesase (updated 2017). 2016 [accessed 2016 December]. http://wwwgoldcopdorg/.
   Google Scholar
• Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–56.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(2):144–9.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Kuna P, Monso E, Costantini M, Petruzzelli S, Sergio F, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104(12):1858–68.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonart diesase. 2011 revision. 2011 [accessed 2013 September]. wwwgoldcopdorg/.
   Google Scholar
• Brightling CE, McKenna S, Hargadon B, Birring S, Green R, Siva R, et al. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax. 2005;60(3):193–8.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–42.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523–5.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA. Eosinophils as biomarkers of chronic obstructive pulmonary disease exacerbation risk. Maybe just for some? Am J Respir Crit Care Med. 2016;193(9):937–8.
   PubMed Web of Science ®Google Scholar
• Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014;9:889–904.
   PubMed Web of Science ®Google Scholar
• White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Worth H, Soler Cataluna JJ, Price D, De Benedetto F, Roche N, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47(2):625–37.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Vogelmeier C, Small M, Higgins V. Understanding the GOLD 2011 strategy as applied to a real-world COPD population. Respir Med. 2014;108(5):729–36.
   PubMed Web of Science ®Google Scholar
• Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: The case against. Eur Respir J. 2009;34(1):13–6.
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco, Osservatorio Nazionale sull'impiego dei Medicinali. L'uso dei farmaci in Italia. Rapporto nazionale 2014. 2014 [accessed 2016 June 8]. www.agenziafarmaco.gov.it.
   Google Scholar
• Ripellino C, Guasconi A, Heiman F. GOLD guidelines adherence impact on the NHS budget. Farmeconomia Health Econ Ther Pathways. 2014;15(1):5–14.
   Google Scholar
• Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis. 2015;10:2535–48.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Andreu I, Romero Y, Sitjar S, Altes A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. Br J Gen Pract. 2012;62(595):e68–75.
   PubMed Web of Science ®Google Scholar
• Pearson M, Ayres JG, Sarno M, Massey D, Price D. Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997–2001. Int J Chron Obstruct Pulmon Dis. 2006;1(4):435–43.
   PubMedGoogle Scholar
• Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res. 2008;9:62.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139(3):505–12.
   PubMed Web of Science ®Google Scholar
• Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–7.
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–36.
   PubMed Web of Science ®Google Scholar
• Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama. 2008;300(20):2407–16.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189–95.
   PubMedGoogle Scholar
• Price DB, Russell R, Mares R, Burden A, Skinner D, Mikkelsen H, et al. Metabolic effects associated with ICS in patients with COPD and comorbid type 2 diabetes: a historical matched cohort study. PloS one. 2016;11(9):e0162903.
   PubMed Web of Science ®Google Scholar
• Tozzi V, Longo F, Pacileo G, Salvatore D, Pinelli N, Morando V. PDTA standard per le patologie croniche. 11 ASL a confronto nella gestione della rete dei servizi per BPCO, tumore polmonare, ictus, scompenso cardiaco e artrite reumatoide. Egea; 2014.
   Google Scholar
• Aisanov Z, Bai C, Bauerle O, Colodenco FD, Feldman C, Hashimoto S, et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int J Chron Obstruct Pulmon Dis. 2012;7:271–82.
   PubMed Web of Science ®Google Scholar
• Davis KJ, Landis SH, Oh YM, Mannino DM, Han MK, van der Molen T, et al. Continuing to confront copd international physician survey: physician knowledge and application of COPD management guidelines in 12 countries. Int J Chron Obstruct Pulmon Dis. 2015;10:39–55.
   PubMed Web of Science ®Google Scholar
• Glaab T, Vogelmeier C, Hellmann A, Buhl R. Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany. Int J Chron Obstruct Pulmon Dis. 2012;7:101–8.
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.
   PubMed Web of Science ®Google Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103(5):692–9.
   PubMed Web of Science ®Google Scholar
• Babu KS, Kastelik JA, Morjaria JB. Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin pharmacol. 2014;78(2):282–300.
   PubMed Web of Science ®Google Scholar
• Worth H, Buhl R, Criee CP, Kardos P, Mailander C, Vogelmeier C. The ‘real-life’ COPD patient in Germany: the DACCORD study. Respir Med. 2016;111:64–71.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonart diesase (updated 2008). 2008 [accessed December 2008]. wwwgoldcopdorg/.
   Google Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106(7):989–97.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Pini L. COPD: it is time to change! Int J Chron Obstruct Pulmon Dis. 2015;10:2451–7.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Puxeddu E, Ciaprini C, Ora J, Onorato A, Pezzuto G, et al. The time course of pulmonary function tests in COPD patients with different levels of blood eosinophils. Bio Med Res Int. 2016;2016:4547953.
   Google Scholar
• Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261(1):274–82.
   PubMed Web of Science ®Google Scholar
• Sun W, Kechris K, Jacobson S, Drummond MB, Hawkins GA, Yang J, et al. Common genetic polymorphisms influence blood biomarker measurements in COPD. PLoS Genet. 2016;12(8):e1006011.
   PubMed Web of Science ®Google Scholar
• Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(7):CD002991.
   PubMed Web of Science ®Google Scholar
• Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agusti A, Anzueto A, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J. 2017;50(1).
   PubMed Web of Science ®Google Scholar
• Halpin DM, Quint JK. The WISDOM of inhaled corticosteroids in COPD. Thorax. 2014;69(12):1071–2.
   PubMed Web of Science ®Google Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371(14):1285–94.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222–34.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115–22.
   PubMed Web of Science ®Google Scholar
• Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58(11):937–41.
   PubMed Web of Science ®Google Scholar
• Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–8.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–8.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387(10030):1817–26.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009;136(4):1029–38.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–23.
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662–71.
   PubMed Web of Science ®Google Scholar
• Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374–82.
   PubMed Web of Science ®Google Scholar
• Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S, et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J. 2007;29(5):906–13.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Tetzlaff K, Vogelmeier C, Fabbri LM, Magnussen H, Wouters EF, et al. Eosinophilia, frequent exacerbations, and steroid response in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017.
   Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population study. Am J Respir Crit Care Med. 2016;193(9):965–74.
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–700.
   PubMed Web of Science ®Google Scholar
• Gruffydd-Jones K, Brusselle G, Jones R, Miravitlles M, Baldwin M, Stewart R, et al. Changes in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: a real-world study. NPJ Prim Care Respir Med. 2016;26:16002.
   PubMed Web of Science ®Google Scholar